查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1087059

黑色素瘤治疗:市场预测(2022年～2027年)

Melanoma Treatment Market - Forecasts from 2022 to 2027
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 120 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球黑色素瘤治疗的市场规模预测将从2020年的35亿8,600万美金，在预测期间内预计将以15.12％的年复合成长率扩大，到2027年达到96亿800万美元。

本报告提供黑色素瘤治疗的世界市场调查，提供市场规模和预测，市场促进因素及课题，市场趋势，各市场区隔的市场分析，竞争情形，主要企业的简介等系统性资讯。

目录

第1章 简介

  • 市场定义
  • 市场区隔

第2章 调查手法

  • 调查资料
  • 假设

第3章 摘要整理

  • 调查的重点

第4章 市场动态

  • 推动市场要素
  • 阻碍市场要素
  • 波特的五力分析
    • 供给企业谈判力
    • 买方议价能力
    • 替代品的威胁
    • 新加入厂商者的威胁
    • 竞争企业间的敌对关係
  • 产业的价值链分析

第5章 黑色素瘤治疗市场:各类型

  • 皮肤黑色素瘤
  • 眼内黑色素瘤
  • 粘膜黑色素瘤

第6章 黑色素瘤治疗市场:不同治疗

  • 手术
  • 免疫疗法
  • 标靶治疗
  • 化疗
  • 放射治疗

第7章 黑色素瘤治疗市场:各地区

  • 简介
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 其他
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 台湾
    • 泰国
    • 印尼
    • 日本
    • 其他

第8章 竞争情形与分析

  • 主要企业策略分析
  • 新兴企业与市场的有利性
  • 合併，收购，协定，及合作
  • 供应商竞争力矩阵

第9章 企业简介

  • Merck & Co. Inc.
  • Amgen Inc.
  • Iovance Biotherapeutics, Inc,
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche Ltd
  • Eisai Co., Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • AstraZeneca
简介目录
Product Code: KSI061610401

The melanoma treatment market is projected to witness a CAGR of 15.12% during the forecast period to reach a market size of US$9.608 billion by 2027, increasing from US$3.586 billion in 2020.

Introduction.

In recent years, there has been a rise in the number of new cases reported due to climatic changes. These changes are increasing the incidence of melanoma patients worldwide, raising the demand for proper methods of treatment. If detected and treated early, the disease is almost always curable. The rising per capita income, better health facilities, growing health awareness, the availability of health insurance services, and advancement in medical science and bio-medicines are additionally factoring in the expansion of the market.

Geographically, North America dominates the market share. The high prevalence of skin-related cancer in the United States is a major factor contributing to the market's growth. By type, cutaneous melanoma is widely spread globally caused by too much exposure to ultraviolet rays from the sun and indoor tanning. Based on therapy, targeted therapy is gaining the market share due to lesser side effects and high efficiency rates.

Growth Factors.

  • Growing regulatory approvals.

The high emphasis and consequently the elevated investment in the development of efficient treatment options are likely to have a positive impact on the growth of the market. Treatment recommendations depend on many factors, and the increasing number of regulatory approvals has made the highest impact on market growth. In 2021, Aldesleukin, Binimetinib, Braftovi (Encorafenib), Cobimetinib Fumarate, Cotellic (Cobimetinib Fumarate), Dabrafenib Mesylate, etc. were some of the approved drugs for the treatment by FDA. The emphasis of significant companies on introducing innovative treatment options and drugs will aid the market's growth in the coming years.

Impact of COVID-19 on the Melanoma Treatment Market

The pandemic has had a lagging effect on various diagnostic methods due to several restrictions and risk exposure of the comorbidity patients. A drastic reduction in skin biopsies was seen early in the COVID-19 pandemic, which disproportionately affected the elderly, females, and certain geographic regions. Efforts have been made by the government to contain the situation without further delay.

Competitive Insights.

The market leaders for the melanoma treatment market are Merck & Co. Inc., Amgen Inc., Iovance Biotherapeutics, Inc, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Eisai Co., Ltd., Novartis AG, Pfizer Inc., Sanofi, and AstraZeneca.

  • In 2021, Oncosec Medical Inc. and Merck and Co. collaborated to study phase III metastatic melanoma.
  • In 2021, Amgen completed the acquisition of Five Prime Therapeutics, a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share and is set to acquire Teneobio, a privately held, clinical-stage biotechnology company.
  • In 2020, Iovance Biotherapeutics, Inc sold $500 million of its common stock, subject to market and other conditions, in an underwritten public offering. In 2021, there has been certain turmoil, and the company is looking for buy-out options.
  • In 2019, Bristol-Myers Squibb Company and Celgene Corporation entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene for approximately $74 billion to create an innovative biopharma company.
  • In 2020, Novartis AG acquired The Medicines Company, and in 2018 GlaxoSmithKline plc reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Joint Venture for $13 billion.
  • In 2020, FDA approved AstraZeneca and Merck & Co.'s drug selumetinib to treat neurofibromatosis type 1, or NF1, a rare and typically inherited disease that causes tumors to grow inside nerve sheaths. Merck joined AstraZeneca in developing and commercializing Koselugo as part of a deal that included the ovarian cancer drug Lynparza.

Segmentation:

  • By Type

Cutaneous Melanoma

Ocular Melanoma

Mucosal Melanoma

  • By Therapy

Surgery

Immunotherapy

Targeted Therapy

Chemotherapy

Radiation Therapy

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • UK
  • Germany
  • France
  • Spain
  • Others

Middle East and Africa

  • Saudi Arabia
  • Israel
  • Others

Asia Pacific

  • Japan
  • China
  • India
  • Indonesia
  • Taiwan
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Powers of Buyers
    • 4.3.3. Threat of Substitutes
    • 4.3.4. The Threat of New Entrants
    • 4.3.5. Competitive Rivalry in Industry
  • 4.4. Industry Value Chain Analysis

5. MELANOMA TREATMENT MARKET BY TYPE

  • 5.1. Cutaneous Melanoma
  • 5.2. Ocular Melanoma
  • 5.3. Mucosal Melanoma

6. MELANOMA TREATMENT MARKET BY THERAPY

  • 6.1. Surgery
  • 6.2. Immunotherapy
  • 6.3. Targeted Therapy
  • 6.4. Chemotherapy
  • 6.5. Radiation Therapy

7. MELANOMA TREATMENT MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom 
    • 7.4.4. Spain 
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Israel
    • 7.5.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. South Korea
    • 7.6.4. Taiwan
    • 7.6.5. Thailand
    • 7.6.6. Indonesia 
    • 7.6.7. Japan
    • 7.6.8. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrative
  • 8.3. Mergers, Acquisition, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

  • 9.1. Merck & Co. Inc.
  • 9.2. Amgen Inc.
  • 9.3. Iovance Biotherapeutics, Inc,
  • 9.4. Bristol-Myers Squibb 
  • 9.5. F. Hoffmann-La Roche Ltd
  • 9.6. Eisai Co., Ltd.
  • 9.7. Novartis AG
  • 9.8. Pfizer Inc.
  • 9.9. Sanofi
  • 9.10. AstraZeneca